Spire Wealth Management Raises Stock Position in IDEXX Laboratories, Inc. $IDXX

Spire Wealth Management grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1,096.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,117 shares of the company’s stock after buying an additional 1,940 shares during the period. Spire Wealth Management’s holdings in IDEXX Laboratories were worth $1,432,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of IDXX. Eastern Bank lifted its position in IDEXX Laboratories by 775.4% in the fourth quarter. Eastern Bank now owns 604 shares of the company’s stock valued at $409,000 after acquiring an additional 535 shares during the last quarter. LVW Advisors LLC boosted its stake in IDEXX Laboratories by 8.9% in the fourth quarter. LVW Advisors LLC now owns 439 shares of the company’s stock valued at $297,000 after acquiring an additional 36 shares in the last quarter. Global X Japan Co. Ltd. grew its holdings in shares of IDEXX Laboratories by 395.9% during the fourth quarter. Global X Japan Co. Ltd. now owns 3,516 shares of the company’s stock worth $2,379,000 after purchasing an additional 2,807 shares during the last quarter. Mather Group LLC. increased its position in shares of IDEXX Laboratories by 1.7% during the fourth quarter. Mather Group LLC. now owns 1,474 shares of the company’s stock worth $997,000 after purchasing an additional 25 shares in the last quarter. Finally, Kathmere Capital Management LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $216,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Nimrata Hunt sold 2,693 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the sale, the executive vice president directly owned 19,899 shares of the company’s stock, valued at $13,163,984.46. This trade represents a 11.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the transaction, the director owned 648 shares in the company, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IDXX. BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. UBS Group decreased their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Finally, Barclays lowered their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $557.09 on Tuesday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a market capitalization of $44.30 billion, a price-to-earnings ratio of 42.62, a price-to-earnings-growth ratio of 3.39 and a beta of 1.66. The firm has a 50-day simple moving average of $628.15 and a 200-day simple moving average of $661.46. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.15. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.